Tumor Immunotherapy by IL-2 and IL-2 Gene Transfected Cells

  • A. Lindemann
  • F. M. Rosenthal
  • A. Mackensen
  • H. Veelken
  • P. Kulmburg
  • M. Lahn
  • R. Mertelsmann
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 37)


Tumortherapy is based on a variety of treatment modalities. Directly operating cytoreductive approaches are designed to work either locally like surgery or radiotherapy, or systemically like cytotoxic drugs. Other ways of treatment are going to exploit the interaction of tumor and host. They are designed to block the host supply of hormones and growth factors the tumor relies on, to inhibit angiogenesis, or to recruit the intrinsic host defense system. The latter is translated into practice by immunotherapy that has made considerable progress recently. Aside from using monoclonal antibodies against tumor associated antigens (TAA) to mediate tumor cytotoxic effects, various approaches to recruit cytotoxic lymphocytes have been worked out.


Renal Cell Carcinoma Minimal Residual Disease Tumor Associate Antigen Autologous Tumor Cell Irradiate Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lindemann, A., Herrmann, F., Oster, W., and Mertelsmann, R.: Lymphokine activated killer cells, Blut 59: 1–10, 1989.CrossRefGoogle Scholar
  2. 2.
    Lindemann, A., Höffken, K., Schmidt, R.E., Diehl, V., Kloke, O., Gamm, H., Hayungs, J., Oster, W., Böhm, M., Kolitz, E., Franks, C.R., Herrmann, F., and Mertelsmann, R.: A phase II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol. Immunother. 28: 275–281, 1989.PubMedCrossRefGoogle Scholar
  3. 3.
    Veelken, H., Rosenthal, F.M., Schneller, F., von Schilling, C., Guettler, I.C., Herrmann, F., Mertelsmann, R., and Lindemann, A.: Combination of interleukin-2 and interferon- α in renal cell carcinoma and malignant melanoma a phase II clinical trial. Biotech. Therap. 3: 1–14, 1992.Google Scholar
  4. 4.
    Rosenberg, S.A., Lotze, M.T., Muul, L.M., Chang, A.E., Avis, F.P., Leitman, S., Linehan, W.M., Robertson, C.N., Lee, R.E., Rubin, J.T., Seipp, C.A. Simpson, C.G., and White D.E.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316: 889–897, 1987.PubMedCrossRefGoogle Scholar
  5. 5.
    Wiebke, E.A., Rosenberg, S.A. Lotze, M.T.: Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J. Clin. Oncol. 6: 1440–1449, 1988.PubMedGoogle Scholar
  6. 6.
    De Plaen, E., Lurquin, A., Van Pel, B., Mariamé, J.P., Szikora, R., Wölfel, T., Sibille C., Chomez, P., and Boon, T.: Turn-variants of mouse mastocytoma P815.IX. Cloning of the gene of tum-antigen P91A and identification of the tum-mutation. Proc. Natl. Acad. Sci USA. 85: 2274–2280, 1988.PubMedCrossRefGoogle Scholar
  7. 7.
    van der Bruggen, Traversari, C., Chomez, P., Lurquin, C., de Plaen, E., van den Eynde, B., Knuth, A., Boon, T.: Gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647, 1991.PubMedCrossRefGoogle Scholar
  8. 8.
    Mackensen, A., Carcelain, G., Viel, S., Raynal, M.C., Michalaki, H., Triebel, F., Bosq, J., and Hercend, Th.: Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest., 1994 in pressGoogle Scholar
  9. 9.
    Greenberg, P.D., Klarner, J.P., Kern, D.E., and Cheever, M.A. Prog. Exp. Tumor Res. 32: 104–127, 1988.PubMedGoogle Scholar
  10. 10.
    Kast, W.M., Offringa, R., Peters, P.J., Voordouw, A.C., Meloen, R.H. van der Eb, A. J. Melief, C.J.M.: Eradication of Adenovirus E1-induced tumors by E1A-specific cytotoxic T Lymphocytes. Cell 59: 603–614, 1989.PubMedCrossRefGoogle Scholar
  11. 11.
    Knuth, A., Wölfel, T., Klehmann, E., Boon, T., and Meyer zum Büschenfelde, K.-H.: Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. USA: 86: 2804–2810, 1989.PubMedCrossRefGoogle Scholar
  12. 12.
    Cantrell, D.A., Smith, A.: The transient expression of interleukin-2 receptors. Consequences for T cell growth. J. Exp. Med. 158: 1895–1905, 1988.CrossRefGoogle Scholar
  13. 13.
    Lindemann, A., Brossart, P., Höffken, K., Flaßihove, M., Voliotis, D., Diehl, V., Hecker, G., Wagner, H., Mertelsmann, R.: Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-1B study. Cancer Immunol. Immunother. 37: 307–315, 1993.CrossRefGoogle Scholar
  14. 14.
    Lindemann, A., Brossart, P., Höffken, K., Flasshove, M., Voliotis, D., Diehl, V., Kulmburg, P., Wagner, H., and Mertelsmann, R.: Serum cytokine levels in cancer patients treated with different schedules of ultra-low-dose interleukin-2. J. of Immunother. 15: 225–230, 1994.CrossRefGoogle Scholar
  15. 15.
    Janeway, Ch.A., and Bottomly, K.: Signals and signs for lymphocyte responses. Cell 76: 275–285, 1994.PubMedCrossRefGoogle Scholar
  16. 16.
    Tepper, R.I., Pattengale, P.K. and Leder, Ph.: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503–512, 1989.PubMedCrossRefGoogle Scholar
  17. 17.
    Hock, H., Dorsch, M., Diamantstein, T., and Blankenstein, Th.: Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J. Exp. Med. 174: 1291–1298, 1991.PubMedCrossRefGoogle Scholar
  18. 18.
    Chen, L., Ashe, S., Brady, W.A., Hellström, I., Hellström, K.E., Ledbetter, J.A., McGowan, P., and Linsley, P.S.: Costimulation of antitumor immunity by the B7 conterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093, 1992.PubMedCrossRefGoogle Scholar
  19. 19.
    Dranoff, G., Jaffee, E., Lazenby, A., Golumber, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H, Pardoll, D, and Mulligan, R.C.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90: 3539–3543, 1993.PubMedCrossRefGoogle Scholar
  20. 20.
    Chen, L., McGowan, P., Ashe, St., Jonston, J., Li, Y., Hellström, I., and Hellström, K.E.: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179: 523–532, 1994.PubMedCrossRefGoogle Scholar
  21. 21.
    Cotton, M., Wagner, E., Birnstiel, M.L.: Recceptor-mediated transport of DNA into eukaryotic cells. Meth. Enzymol. 217: 618–644, 1993.CrossRefGoogle Scholar
  22. 22.
    Tahara, H., Zeh, H.J. 3rd, Storkus, W.J., Pappo, I., Watkins, S.C., Gubler, U., Wolf S.F., Robbins, P.D., Lotze, M.T.: Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54: 182–189, 1994.PubMedGoogle Scholar
  23. 23.
    Veelken, H., Jesuiter, H., Rosenthal, F.M., Mackensen, A., Kulmburg, Pl. Schultze, J., Wagner, E., Mertelsmann, R., and Lindemann, A.: Primary fibroblasts form human adults as target cells for ex vivo transfection and gene therapy. Human Gene Therapy, in press.Google Scholar
  24. 24.
    Huang, A.Y.C., Golumbek, P., Jaffee, E.M., Ahmadzadeh, M., Pardoll D.M., and Levitsky, H.: Host bone marrow derived cells, not tumor cells, present MHC closs I restricted tumor antigens in priming of antitumor immune response. J. of Cell. Biochem. Suppl. 18D, V168, 1994.Google Scholar
  25. 25.
    Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M., and Pardoll, D.M.: Treatment of established renal cancer by tumor cells engineered to secrete inter-leukin-4. Science 254: 713–716, 1991.PubMedCrossRefGoogle Scholar
  26. 26.
    Riethmüller, G., Schneider-Gädicke, E., Schlimck, G., Schmiegel, W., Raab, R., Höffken, K., Gruber R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J.: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’C col orectal carcinoma. The Lancet 343: 1177–1183, 1994.CrossRefGoogle Scholar
  27. 27.
    Berd, D., Mastrangelo, M.J.: Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T suppressor function without depletion of the CD8+ subset. Cancer Res. 47: 3317–3322, 1987.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • A. Lindemann
    • 1
  • F. M. Rosenthal
    • 1
  • A. Mackensen
    • 1
  • H. Veelken
    • 1
  • P. Kulmburg
    • 1
  • M. Lahn
    • 1
  • R. Mertelsmann
    • 1
  1. 1.Department Medicine I, Hematology and OncologyUniversity of FreiburgGermany

Personalised recommendations